Copaxone Supreme Court Case Could Cut Relitigation Of Patent Claims
Supreme Court to hear oral arguments in case that could restrict the ability of the Federal Circuit to overturn certain rulings on patent claim terms; Google, Intel and other tech companies back Sandoz.
You may also be interested in...
Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.
Agencies seek public comment on how they can modernize merger guidelines to enforce antitrust laws. List of questions, including what types of evidence show that a merger could reduce competition, indicate pharma and other mergers will face greater scrutiny.
With the Winter Games approaching, case offers lesson for companies with complex advertising packages. Lilly told the agency two commercials featuring Olympic and Paralympic athletes were intended to run sequentially with another ad including indication and risk information.